A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
Public ClinicalTrials.gov record NCT01810939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia
Study identification
- NCT ID
- NCT01810939
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Relypsa, Inc.
- Industry
- Enrollment
- 243 participants
Conditions and interventions
Conditions
Interventions
- Patiromer Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2013
- Primary completion
- Jun 30, 2013
- Completion
- Jul 31, 2013
- Last update posted
- Jun 2, 2021
2013
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 3121 | Azusa | California | 91702 | — |
| Investigator Site 3133 | Los Angeles | California | 90025 | — |
| Investigator Site 3103 | Sacramento | California | 95825 | — |
| Investigator Site 3129 | Santa Barbara | California | 93110 | — |
| Investigator Site 3130 | Ventura | California | 93003 | — |
| Investigator Site 3105 | Edgewater | Florida | 32132 | — |
| Investigator Site 3113 | Hollywood | Florida | 33021 | — |
| Investigator Site 3106 | Port Charlotte | Florida | 33952 | — |
| Investigator Site 3120 | Augusta | Georgia | 30909 | — |
| Investigator Site 3102 | Farmington | Missouri | 63640 | — |
| Investigator Site 3104 | Kansas City | Missouri | 64111 | — |
| Investigator Site 3134 | Flushing | New York | 11355 | — |
| Investigator Site 3107 | Bethlehem | Pennsylvania | 18017 | — |
| Investigator Site 3110 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01810939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01810939 live on ClinicalTrials.gov.